



May 1, 2017

## Acceleron to Participate in Two Healthcare Investor Conferences in May

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that senior management will participate in two upcoming healthcare investor conferences in May.

### Conference Details:

Event: Deutsche Bank 42nd Annual Health Care Conference  
Date/Time: May 4, 2017 at 8:40 a.m. EDT  
Location: Boston, MA

Event: UBS Global Healthcare Conference  
Date/Time: May 22, 2017 at 10:30 a.m. EDT  
Location: New York, NY

A live audio webcast for the Deutsche Bank and UBS Healthcare Conferences will be available on the Investors/Media page of the Company's website at [www.acceleronpharma.com](http://www.acceleronpharma.com). A replay of the webcast will be available approximately two hours after the event on the Acceleron website.

### About Acceleron

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases. Its pioneering research platform leverages the powerful biology behind the body's ability to rebuild and repair its own cells and tissues. This approach to drug discovery has generated four therapeutic candidates that are currently in clinical trials. The Company's lead therapeutic candidate, luspatercept, is being evaluated in Phase 3 studies for the treatment of the hematologic diseases myelodysplastic syndromes (MDS) and beta-thalassemia under a global partnership with Celgene Corp. Acceleron is also advancing clinical programs in the fields of oncology and neuromuscular diseases and has a comprehensive preclinical research effort targeting fibrotic and other serious diseases.

For more information, please visit [www.acceleronpharma.com](http://www.acceleronpharma.com). Follow Acceleron on Social Media: [@AcceleronPharma](https://twitter.com/AcceleronPharma) and [LinkedIn](https://www.linkedin.com/company/acceleron-pharma).

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20170501005095/en/>

Acceleron Pharma Inc.  
Todd James, IRC, 617-649-9393  
Senior Director, Investor Relations and Corporate Communications  
or  
Media:  
BMC Communications  
Brad Miles, 646-513-3125

Source: Acceleron Pharma Inc.

News Provided by Acquire Media